JP2018517760A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517760A5 JP2018517760A5 JP2017566026A JP2017566026A JP2018517760A5 JP 2018517760 A5 JP2018517760 A5 JP 2018517760A5 JP 2017566026 A JP2017566026 A JP 2017566026A JP 2017566026 A JP2017566026 A JP 2017566026A JP 2018517760 A5 JP2018517760 A5 JP 2018517760A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- cycloalk
- formula
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 13
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 208000018360 neuromuscular disease Diseases 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 2
- 208000035902 Critical illness myopathy Diseases 0.000 claims 2
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 229960002362 neostigmine Drugs 0.000 claims 2
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 claims 2
- 230000002232 neuromuscular Effects 0.000 claims 2
- 229960002290 pyridostigmine Drugs 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 claims 1
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 claims 1
- UMVSOHBRAQTGQI-UPZYVNNASA-N Lactucopicrin Natural products O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@@H]2C(CO)=CC(=O)C2=C(C)C1)Cc1ccc(O)cc1 UMVSOHBRAQTGQI-UPZYVNNASA-N 0.000 claims 1
- LHXOCOHMBFOVJS-OAHLLOKOSA-N Ladostigil Chemical compound CCN(C)C(=O)OC1=CC=C2CC[C@@H](NCC#C)C2=C1 LHXOCOHMBFOVJS-OAHLLOKOSA-N 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 1
- OMHBPUNFVFNHJK-UHFFFAOYSA-P ambenonium Chemical compound C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl OMHBPUNFVFNHJK-UHFFFAOYSA-P 0.000 claims 1
- 229960000451 ambenonium Drugs 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229940054025 carbamate anxiolytics Drugs 0.000 claims 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical group C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 201000002342 diabetic polyneuropathy Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 229960003748 edrophonium Drugs 0.000 claims 1
- 229960004979 fampridine Drugs 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- QCDLLIUTDGNCPO-UHFFFAOYSA-N lactupicrin Natural products C12OC(=O)C(=C)C2C(O)CC(C)=C(C(C=2)=O)C1C=2COC(=O)CC1=CC=C(O)C=C1 QCDLLIUTDGNCPO-UHFFFAOYSA-N 0.000 claims 1
- 229950008812 ladostigil Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 239000000842 neuromuscular blocking agent Substances 0.000 claims 1
- 125000001792 phenanthrenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 claims 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 1
- 229960001697 physostigmine Drugs 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 208000025223 poliovirus infection Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175590P | 2015-06-15 | 2015-06-15 | |
| US62/175,590 | 2015-06-15 | ||
| PCT/DK2016/050186 WO2016202341A1 (en) | 2015-06-15 | 2016-06-15 | Compounds for use in treating neuromuscular disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517760A JP2018517760A (ja) | 2018-07-05 |
| JP2018517760A5 true JP2018517760A5 (enExample) | 2019-08-08 |
| JP6798075B2 JP6798075B2 (ja) | 2020-12-09 |
Family
ID=56409450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566026A Active JP6798075B2 (ja) | 2015-06-15 | 2016-06-15 | 神経筋障害を処置するのにおける使用のための化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10934244B2 (enExample) |
| EP (1) | EP3307262B1 (enExample) |
| JP (1) | JP6798075B2 (enExample) |
| KR (1) | KR102722949B1 (enExample) |
| CN (1) | CN107820425B (enExample) |
| AU (1) | AU2016279486B2 (enExample) |
| BR (1) | BR112017026739A2 (enExample) |
| CA (1) | CA2986611C (enExample) |
| DK (1) | DK3307262T3 (enExample) |
| ES (1) | ES2879826T3 (enExample) |
| IL (1) | IL256166B (enExample) |
| MX (1) | MX389242B (enExample) |
| RU (1) | RU2745065C2 (enExample) |
| WO (1) | WO2016202341A1 (enExample) |
| ZA (1) | ZA201707852B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| EA020856B1 (ru) | 2009-02-16 | 2015-02-27 | Джулиани Интернэшнл Лимитед | Способы лечения патологических состояний, связанных с волосами |
| JP6301844B2 (ja) | 2012-02-09 | 2018-03-28 | ノグラ ファーマ リミテッド | 線維症の処置方法 |
| KR102722949B1 (ko) | 2015-06-15 | 2024-10-28 | 엔엠디 파마 에이/에스 | 신경근 장애의 치료에 사용하기 위한 화합물 |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US20190183812A1 (en) * | 2017-12-14 | 2019-06-20 | Nmd Pharma A/S | Compounds For The Treatment Of Neuromuscular Disorders |
| TWI780281B (zh) | 2017-12-14 | 2022-10-11 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) * | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| TW201927738A (zh) * | 2017-12-14 | 2019-07-16 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| TWI794369B (zh) * | 2017-12-14 | 2023-03-01 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
| WO2019241663A1 (en) | 2018-06-15 | 2019-12-19 | Afecta Pharmaceuticals, Inc. | Ccl5 inhibitors |
| CN111035813B (zh) * | 2018-10-15 | 2022-02-18 | 复旦大学附属中山医院 | 一种液体创可贴式冠脉带膜支架及其制作方法 |
| EP3921299B1 (en) | 2019-02-08 | 2024-11-20 | Nogra Pharma Limited | Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
| US12415771B2 (en) * | 2019-06-19 | 2025-09-16 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| IL287901B2 (en) * | 2019-06-19 | 2025-02-01 | Nmd Pharma As | Process for preparing CLC-1 chloride channel inhibitors |
| EP3753560A1 (en) * | 2019-06-19 | 2020-12-23 | NMD Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| EP3986853A1 (en) | 2019-06-19 | 2022-04-27 | NMD Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| JP7834315B2 (ja) * | 2021-10-29 | 2026-03-24 | 学校法人関西医科大学 | 重症筋無力症治療薬 |
| WO2024261020A1 (en) | 2023-06-20 | 2024-12-26 | Nmd Pharma A/S | Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases |
| WO2025196186A1 (en) * | 2024-03-20 | 2025-09-25 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| WO2025196206A1 (en) * | 2024-03-20 | 2025-09-25 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA676827A (en) | 1963-12-24 | The Sherwin-Williams Company Of Canada Limited | Herbicidal compositions | |
| GB573476A (en) | 1943-04-21 | 1945-11-22 | Reginald Thomas Foster | Improvements in or relating to the manufacture of chlorinated phenoxy compounds |
| GB822199A (en) | 1956-09-18 | 1959-10-21 | Boots Pure Drug Co Ltd | Process for the preparation of alpha-phenoxyalkanoic acids |
| FR1451171A (fr) | 1961-04-21 | 1966-01-07 | Jacques Logeais Soc D Expl Des | Dérivés éthérifiés et estérifiés de l'o-hydroxy-phényl-2 oxadiazole-1, 3, 4 et leur procédé de préparation |
| US3544560A (en) | 1968-07-19 | 1970-12-01 | Carter Wallace | Penicillin compounds |
| FR2306697A1 (fr) | 1975-04-10 | 1976-11-05 | Sogeras | Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants |
| JPS5219632U (enExample) | 1975-07-30 | 1977-02-12 | ||
| IT1065062B (it) * | 1975-08-08 | 1985-02-25 | Hoffmann La Roche | Esteri di acidi alfa arilossicar bossilici sostituiti |
| US4283472A (en) | 1980-02-26 | 1981-08-11 | Eastman Kodak Company | Silver halide elements containing blocked pyrazolone magenta dye-forming couplers |
| US4337267A (en) | 1980-08-25 | 1982-06-29 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenalkoxyalkyl- and phenoxyalkyl-substituted oxiranecarboxylic acids, their use and medicaments containing them |
| DE3460315D1 (en) | 1983-02-19 | 1986-08-28 | Beecham Group Plc | Benzofuran and benzothiophene-carboxylic-acid derivatives |
| FR2551063A1 (fr) | 1983-08-22 | 1985-03-01 | Inst Nat Sante Rech Med | Nouveaux dimethyl-2,5 pyrroles, leur procede de preparation et leur application en therapeutique |
| FI870445A7 (fi) | 1985-06-14 | 1987-02-02 | Pfizer | Välituote asymmetrisen hydantoiinin valmistuksessa. |
| NO170884C (no) | 1986-08-18 | 1992-12-23 | Hoffmann La Roche | Analogifremgangsmaate ved fremstilling av terapeutisk aktive pyrimidinderivater |
| US4803301A (en) | 1988-04-13 | 1989-02-07 | Kirin Beer Kabushiki Kaisha | Process for producing optically active 2-phenoxypropionic acid |
| US5192785A (en) | 1989-09-03 | 1993-03-09 | A. H. Robins Company, Incorporated | Sulfamates as antiglaucoma agents |
| US5025031A (en) | 1989-11-30 | 1991-06-18 | A. H. Robins Co., Inc. | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants |
| ATE144538T1 (de) | 1991-04-25 | 1996-11-15 | Romano Deghenghi | Lhrh-antagonisten |
| TW259690B (enExample) | 1992-08-01 | 1995-10-11 | Hoechst Ag | |
| DE4314962A1 (de) | 1993-05-06 | 1994-11-10 | Bayer Ag | Substituierte Piperazine |
| EP0632008B1 (en) | 1993-06-01 | 1998-02-04 | Ono Pharmaceutical Co., Ltd. | Pentanoic acid derivatives |
| EP0971892A1 (en) | 1997-03-25 | 2000-01-19 | Astra Pharmaceuticals Limited | Novel pyridine derivatives and pharmaceutical compositions containing them |
| AU2001241512A1 (en) * | 2000-03-13 | 2001-09-24 | Eli Lilly And Company | Sulfonamide derivatives |
| US20020013295A1 (en) * | 2000-05-30 | 2002-01-31 | Slusher Barbara S. | Naaladase inhibitors for treating amyotrophic lateral sclerosis |
| MXPA03006467A (es) | 2001-01-17 | 2004-01-29 | Guilford Pharm Inc | Inibidores de naaladasa a base de tiol. |
| GB0106586D0 (en) | 2001-03-16 | 2001-05-09 | Smithkline Beecham Plc | Novel compounds |
| US7271181B2 (en) * | 2001-05-11 | 2007-09-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| AU2002325614A1 (en) | 2001-08-16 | 2003-03-03 | Pharmacon-Forschung Und Beratung Gmbh | Compounds containing lactic acid elements, method for the production and use thereof as pharmaceutically active substances |
| CA2515939A1 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Novel compounds |
| BRPI0408353A (pt) | 2003-03-28 | 2006-03-21 | Lilly Co Eli | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto |
| SE0301009D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| US7034051B2 (en) | 2003-08-28 | 2006-04-25 | Adolor Corporation | Fused bicyclic carboxamide derivatives and methods of their use |
| GB0409921D0 (en) | 2004-05-04 | 2004-06-09 | Novartis Ag | Organic compounds |
| US20080200499A1 (en) | 2004-07-20 | 2008-08-21 | Reiner Fischer | Selective Insecticides and/or Acaricides Based on Substituted Cyclic Dicarbonyl Compounds and Safeners |
| DE102004035131A1 (de) | 2004-07-20 | 2006-02-16 | Bayer Cropscience Ag | Selektive Insektizide und/oder Akarizide auf Basis von substituierten, cyclischen Dicarbonylverbindungen und Safenern |
| GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| US20080254983A1 (en) | 2005-09-16 | 2008-10-16 | Nufarm Australia Limited | Herbicide Composition |
| WO2007057767A2 (en) | 2005-11-17 | 2007-05-24 | Pfizer Limited | Amino acid derivatives |
| WO2007062678A1 (en) * | 2005-11-29 | 2007-06-07 | 7Tm Pharma A/S | Phenoxyacetic acid derivatives as crth2 receptor ligands |
| GB0524428D0 (en) * | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Medicinal use of receptor ligands |
| DE602007009873D1 (de) | 2006-12-11 | 2010-11-25 | Merck Sharp & Dohme | Substituierte diazepin-sulfonamide als bombesin-rezeptor-subtyp-3-modulatoren |
| AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| FR2917424B1 (fr) | 2007-06-12 | 2012-10-19 | Inst Francais Du Petrole | Production de charges de vapocraquage a haut rendement en ethylene, propylene et polymeres resultants par hydrotraitement d'huile vegetales |
| US8742183B2 (en) | 2007-12-21 | 2014-06-03 | Uop Llc | Production of aviation fuel from biorenewable feedstocks |
| US8324438B2 (en) | 2008-04-06 | 2012-12-04 | Uop Llc | Production of blended gasoline and blended aviation fuel from renewable feedstocks |
| CN101402537B (zh) | 2008-11-12 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 2-吡啶-β酮类化合物的应用 |
| MX2011011094A (es) | 2009-04-20 | 2011-11-04 | Hoffmann La Roche | Derivados de prolina como inhibidores de catepsina. |
| US8394900B2 (en) | 2010-03-18 | 2013-03-12 | Syntroleum Corporation | Profitable method for carbon capture and storage |
| EP2560488B1 (en) * | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| CA2805452C (en) | 2010-07-05 | 2018-07-31 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
| WO2012155199A1 (en) | 2011-05-16 | 2012-11-22 | Bionomics Limited | Amine derivatives as potassium channel blockers |
| TR201808305T4 (tr) | 2011-07-13 | 2018-07-23 | Microbiotix Inc | Bakteriyel tip ııı sekresyon sisteminin inhibitörleri. |
| FR2978643B1 (fr) | 2011-08-02 | 2014-01-31 | Ard Sa | Composition herbicide a efficacite amelioree, methode de preparation et utilisation |
| EP2758385B1 (en) * | 2011-09-19 | 2018-03-28 | MSN Laboratories Limited | Process for the preparation of triazole antifungal drug, its intermediates and polymorphs thereof |
| AR089771A1 (es) | 2012-01-31 | 2014-09-17 | Lilly Co Eli | Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| CN102771479B (zh) | 2012-08-31 | 2014-04-16 | 广西田园生化股份有限公司 | 一种含环嗪酮与苯氧羧酸类的除草组合物 |
| US9872865B2 (en) * | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
| AR097631A1 (es) | 2013-09-16 | 2016-04-06 | Bayer Pharma AG | Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos |
| EP3046912A1 (de) | 2013-09-16 | 2016-07-27 | Bayer Pharma Aktiengesellschaft | Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten |
| CN105440020B (zh) | 2013-12-10 | 2018-12-18 | 常州大学 | 具有抗肿瘤活性的1,2,3-三唑类化合物及其制备方法 |
| JP2015231988A (ja) | 2014-05-12 | 2015-12-24 | 大正製薬株式会社 | ２−ピリドン化合物 |
| US10513521B2 (en) | 2014-07-15 | 2019-12-24 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting BMP |
| KR102722949B1 (ko) | 2015-06-15 | 2024-10-28 | 엔엠디 파마 에이/에스 | 신경근 장애의 치료에 사용하기 위한 화합물 |
| KR101829102B1 (ko) | 2015-09-25 | 2018-02-14 | 경희대학교 산학협력단 | 크로마논 2-카르복실산 유도체, 크로만 2-카르복실산 유도체 및 이의 제조방법 |
| AU2016371600B2 (en) | 2015-12-15 | 2021-02-18 | Merck Sharp & Dohme Llc | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
| RU2019123404A (ru) | 2016-12-27 | 2021-02-01 | Дайити Санкио Компани, Лимитед | Производное пиримидина |
| TWI780281B (zh) | 2017-12-14 | 2022-10-11 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
-
2016
- 2016-06-15 KR KR1020187001054A patent/KR102722949B1/ko active Active
- 2016-06-15 ES ES16738352T patent/ES2879826T3/es active Active
- 2016-06-15 CA CA2986611A patent/CA2986611C/en active Active
- 2016-06-15 WO PCT/DK2016/050186 patent/WO2016202341A1/en not_active Ceased
- 2016-06-15 RU RU2017143609A patent/RU2745065C2/ru active
- 2016-06-15 AU AU2016279486A patent/AU2016279486B2/en active Active
- 2016-06-15 EP EP16738352.0A patent/EP3307262B1/en active Active
- 2016-06-15 MX MX2017016424A patent/MX389242B/es unknown
- 2016-06-15 JP JP2017566026A patent/JP6798075B2/ja active Active
- 2016-06-15 DK DK16738352.0T patent/DK3307262T3/da active
- 2016-06-15 BR BR112017026739-0A patent/BR112017026739A2/en not_active Application Discontinuation
- 2016-06-15 CN CN201680034824.8A patent/CN107820425B/zh active Active
- 2016-06-15 US US15/736,756 patent/US10934244B2/en active Active
-
2017
- 2017-11-20 ZA ZA2017/07852A patent/ZA201707852B/en unknown
- 2017-12-07 IL IL256166A patent/IL256166B/en active IP Right Grant